FDA leans on another compound pharmacy for manufacturing problems
from The Wall Street Journal
Once again, the FDA has taken a tough stance against a compound pharmacy with quality-control problems that led to product recalls and concerns over patient safety. In this latest instance, the agency obtained a consent decree that prohibits Specialty Compounding from making or distributing injectable sterile medicines until the company complies with federal law governing manufacturing practices.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063